NASDAQ: LMRILumexa Imaging Holdings Inc Stock
$10.00+0.43 (+4.49%)
Updated May 1, 2026
LMRI Price
$10.00
Fair Value Price
N/A
Market Cap
$961.10M
52 Week Low
$7.23
52 Week High
$19.45
P/E
-15.15x
P/B
1.64x
P/S
1.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.02B
Earnings
-$47.10M
Gross Margin
15.4%
Operating Margin
8.44%
Profit Margin
-4.6%
Debt to Equity
2.01
Operating Cash Flow
$17M
Beta
2.7
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LMRI Overview
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. The company was founded in 2018 and is based in Raleigh, North Carolina.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LMRI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LMRI
Ranked#50 of 95
Ranked#50 of 95
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.11 | A | |
| $9.97 | A | |
| $25.60 | A |
Be the first to know about important LMRI news, forecast changes, insider trades & much more!
LMRI News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LMRI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LMRI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LMRI is good value based on its book value relative to its share price (1.64x), compared to the US Medical Devices industry average (3.03x)
P/B vs Industry Valuation
LMRI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LMRI due diligence checks available for Premium users.
Valuation
LMRI fair value
Fair Value of LMRI stock based on Discounted Cash Flow (DCF)
Price
$10.00
Fair Value
-$11.18
Undervalued by
189.47%
LMRI is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LMRI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-15.15x
Industry
20.42x
Market
18.83x
LMRI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.64x
Industry
3.03x
LMRI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LMRI's financial health
Profit margin
Revenue
$267.7M
Net Income
-$28.7M
Profit Margin
-10.7%
LMRI's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LMRI's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$1.2B
Debt to equity
2.01
LMRI's short-term assets ($227.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LMRI's long-term liabilities ($999.24M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LMRI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$17.1M
Investing
-$2.4M
Financing
$43.9M
LMRI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LMRI vs Medical Device Stocks
Lumexa Imaging Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.